Biomarker-driven objective probe enactment Precision for Medicine connected Thursday announced the results of a next-generation sequencing (NGS) inaugural which improved the accuracy and velocity of identifying crab mutations successful coagulated tumors.
“This inaugural unveiled the genomic profiles of thousands of tumors successful our biospecimen library, making them almighty gathering blocks for exploring illness drivers, cause targets, diagnostic discovery, and detecting caller mutations ne'er identified before,” Darren Davis, elder vice president astatine Precision, said successful a statement.
The inaugural was portion of a two-year collaboration task with Thermo Fisher, during which Precision performed a wide screening of samples taken from the company’s biorepository for cardinal mutations crossed 11 crab indications, including lung, colon, prostate, melanoma, thyroid, and bladder, Precision said.
This signifier of the inaugural utilized Precision’s formalin-fixed, paraffin-embedded (FFPE) tumor tissues. The tumors were screened connected Thermo’s Ion Torrent Genexus System with the Thermo Fisher Oncomine Precision Assay GX.
“Aided by precocious automation, much than 15,000 tumor samples were screened, with occurrence rates exceeding 90% and with mutation prevalence identified successful much than 75% of tissues,” Davis added. “Accelerating the validation and regulatory support process volition yet pb to faster improvement of personalized (targeted) therapeutics and diagnostics for patients.”
Davis indicated that Precision would proceed screening further subjects to make a go-forward registry, which “will incorporated further NGS assay contented and caller liquid trial methods, to make an enriched biorepository and database derived from tissue-whole humor specimens.”
The results of this collaboration volition beryllium presented astatine the Association for Molecular Pathology (AMP) Annual Meeting and Expo successful Phoenix, Precision said.
English (US)